MA40998A - Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés - Google Patents

Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés

Info

Publication number
MA40998A
MA40998A MA040998A MA40998A MA40998A MA 40998 A MA40998 A MA 40998A MA 040998 A MA040998 A MA 040998A MA 40998 A MA40998 A MA 40998A MA 40998 A MA40998 A MA 40998A
Authority
MA
Morocco
Prior art keywords
envenimation
systems
well
pharmaceutical kits
therapies against
Prior art date
Application number
MA040998A
Other languages
English (en)
Inventor
Matthew R Lewin
Original Assignee
Ophirex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ophirex Inc filed Critical Ophirex Inc
Publication of MA40998A publication Critical patent/MA40998A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Cephalosporin Compounds (AREA)
MA040998A 2014-11-21 2015-11-19 Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés MA40998A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462082895P 2014-11-21 2014-11-21
US201562131441P 2015-03-11 2015-03-11
US201562243374P 2015-10-19 2015-10-19

Publications (1)

Publication Number Publication Date
MA40998A true MA40998A (fr) 2017-09-26

Family

ID=56014685

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040998A MA40998A (fr) 2014-11-21 2015-11-19 Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés

Country Status (18)

Country Link
US (2) US11000506B2 (fr)
EP (1) EP3220902A4 (fr)
JP (1) JP6883515B2 (fr)
KR (2) KR20170086089A (fr)
CN (1) CN107249578B (fr)
AU (1) AU2015349774B2 (fr)
BR (1) BR112017010495B1 (fr)
CA (1) CA2968383C (fr)
CR (1) CR20170259A (fr)
EA (1) EA037262B1 (fr)
IL (1) IL252418B (fr)
MA (1) MA40998A (fr)
MX (1) MX387186B (fr)
MY (1) MY187053A (fr)
PH (1) PH12017500927A1 (fr)
SG (1) SG11201704106VA (fr)
TW (1) TWI745280B (fr)
WO (1) WO2016081826A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017152114A1 (fr) * 2016-03-04 2017-09-08 Jeffrey Alan Klein Administration de médicament antivenin par tumescence
AU2017257185B8 (en) * 2016-04-29 2023-07-06 Ophirex, Inc. Phospholipase A2 inhibitors for immediate treatment of venom toxicity that causes hemolysis, cerebral edema, and acute kidney injury
US20200009071A1 (en) * 2016-12-16 2020-01-09 The Regents Of The University Of California Neutralizing venomous biomacromolecules
AU2018220515B2 (en) * 2017-02-17 2022-06-30 DayLife LLC Universal antivenom
CN108703975A (zh) * 2018-08-30 2018-10-26 黄汝怡 一种治疗毒虫叮咬的涂抹剂
CN109260196A (zh) * 2018-11-08 2019-01-25 中国科学院海洋研究所 巴马司他作为制备水母皮炎药物的应用
US12564575B2 (en) 2019-10-15 2026-03-03 Ophirex, Inc Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis
CN115379836A (zh) * 2019-10-15 2022-11-22 奥菲瑞克斯公司 脓毒症和脓毒症样综合征的早期管理和预防
CN112494498A (zh) * 2020-12-11 2021-03-16 中国人民解放军海军军医大学 四环素在制备预防或缓解水母蜇伤药物中的应用
WO2022216953A1 (fr) * 2021-04-08 2022-10-13 Believe In A Cure, Inc. Composés destinés à être utilisés pour augmenter l'expression de foxg1
US12285408B2 (en) * 2021-05-14 2025-04-29 Liverpool School Of Tropical Medicine Methods and compositions for the treatment of snake bite
KR102726781B1 (ko) * 2021-06-22 2024-11-06 전남대학교산학협력단 한국형 살무사과 사독의 항사독 조성물
CN113817738B (zh) * 2021-10-20 2023-06-16 湖南科技学院 银杏长链非编码rna及其在银杏内酯生物合成中的应用
WO2023086343A1 (fr) * 2021-11-09 2023-05-19 Ophirex, Inc. Compositions et formes pharmaceutiques pour administration topique et transdermique de principes actifs et méthodes d'utilisation
KR102891833B1 (ko) 2022-03-04 2025-11-28 한국원자력의학원 다라플라딥 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 방사선 조사에 의한 피부질환 예방 또는 치료용 약학 조성물
CN117462543A (zh) * 2023-11-02 2024-01-30 南昌大学 一种蛇毒治疗组合物及应用
WO2026002883A1 (fr) 2024-06-24 2026-01-02 Alexander Ruebben Préparation combinée comprenant du varespladib et un agent chélateur de dimercapto pour le traitement et/ou la prophylaxie des morsures de serpent

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196193A (en) 1989-10-31 1993-03-23 Ophidian Pharmaceuticals, Inc. Antivenoms and methods for making antivenoms
MX9501608A (es) 1994-04-01 1997-02-28 Lilly Co Eli 1h-indol-3-glioxilamidas inhibidoras de spla2.
AUPP076797A0 (en) 1997-12-05 1998-01-08 Active (Pla) R&D Pty Ltd Phospholipase inhibitor
WO2004034963A2 (fr) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methodes et compositions utilisant des inhibiteurs de la cholinesterase
US20040254146A1 (en) 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
US20030225031A1 (en) 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
ES2288222T3 (es) 2003-04-14 2008-01-01 Lts Lohmann Therapie-Systeme Ag Parche terapeutico con matriz de polisiloxano que comprende capsaicina.
US20070093518A1 (en) 2003-09-19 2007-04-26 Wetherell Janet R Pharmaceutical compositions for the treatment of organophosphate poisoning
US20050192243A1 (en) 2003-10-28 2005-09-01 Savarese John J. Neuromuscular blocking agents and antagonists thereof
US20070026079A1 (en) 2005-02-14 2007-02-01 Louis Herlands Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
US8546526B2 (en) 2005-10-12 2013-10-01 Advanced Accelerator Applications Selective αvβ3 receptor peptide antagonist for therapeutic and diagnostic applications
EP2069377A4 (fr) 2006-09-27 2009-11-11 Univ California Procédés et compositions pour le traitement de maladies et de troubles de la peau
US20090062369A1 (en) * 2007-08-31 2009-03-05 Joaquim Trias Use of secretory phospholipase a2 (spla2) inhibitors to decrease spla2 levels
WO2009047762A1 (fr) * 2007-10-09 2009-04-16 Yeda Research And Development Co. Ltd Compositions et peptides pour le traitement d'une envenimation par des venins contenant pla2 de type venin bungarus multicinctus
EP2244728B1 (fr) 2008-01-21 2016-08-31 Dermadis Utilisation d'inhibiteurs de sérine protéases pour traiter des maladies de peau
CA2751884C (fr) 2009-01-14 2018-09-25 Corium International, Inc. Administration transdermique de tamsulosine
US20120232031A1 (en) 2009-10-19 2012-09-13 Panmira Pharmaceuticals, Llc Injectable formulations for intra-articular or peri-articular administration
US20130253060A1 (en) * 2011-09-21 2013-09-26 Harihara M. Mehendale Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS)
DK2790758T3 (da) 2011-12-16 2017-11-20 Indosys Ltd Kassette til en lægemiddeldosis og tilførselsindretning
AU2013312240A1 (en) * 2012-09-10 2015-03-19 Ophirex Inc. Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade
US20140087003A1 (en) 2012-09-21 2014-03-27 Ignacio Cisneros Method for treating venomous bites and stings

Also Published As

Publication number Publication date
EP3220902A2 (fr) 2017-09-27
KR102885213B1 (ko) 2025-11-14
CN107249578B (zh) 2021-01-26
CN107249578A (zh) 2017-10-13
BR112017010495B1 (pt) 2023-12-05
KR20170086089A (ko) 2017-07-25
AU2015349774A1 (en) 2017-06-01
AU2015349774B2 (en) 2020-07-02
TW201632204A (zh) 2016-09-16
JP2017536372A (ja) 2017-12-07
TWI745280B (zh) 2021-11-11
BR112017010495A2 (pt) 2018-04-03
SG11201704106VA (en) 2017-06-29
WO2016081826A3 (fr) 2016-07-14
EP3220902A4 (fr) 2018-11-07
CA2968383C (fr) 2024-03-12
US20210260029A1 (en) 2021-08-26
MX387186B (es) 2025-03-18
MY187053A (en) 2021-08-27
IL252418B (en) 2021-01-31
US11000506B2 (en) 2021-05-11
US12274691B2 (en) 2025-04-15
WO2016081826A2 (fr) 2016-05-26
IL252418A0 (en) 2017-07-31
US20170354642A1 (en) 2017-12-14
CR20170259A (es) 2017-10-02
MX2017006551A (es) 2018-01-15
EA037262B1 (ru) 2021-03-01
CA2968383A1 (fr) 2016-05-26
EA201791122A1 (ru) 2018-04-30
JP6883515B2 (ja) 2021-06-09
KR20240117660A (ko) 2024-08-01
PH12017500927A1 (en) 2017-11-20

Similar Documents

Publication Publication Date Title
MA40998A (fr) Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés
NO2023013I1 (no) Combination of foslevodopa and foscarbidopa, each in all forms protected by the basic patent
PL4074331T3 (pl) Kompozycje i sposoby internalizacji enzymów
HUE054159T2 (hu) HPK1 gátlók és azok alkalmazási módja
EP3331549A4 (fr) Molécules améliorées aptes à se lier à des microbes, et leurs utilisations
EP3205046A4 (fr) Systèmes et procédés de partage sécurisé de clé
EP3353703A4 (fr) Approbation mutuelle pour traitement informatique préservant la confidentialité
EP3226856A4 (fr) Traitements combinés
EP3138231A4 (fr) Systèmes et procédés de traitement sécurisé
EP3095027A4 (fr) Application logicielle et zones
EP3102670A4 (fr) Systèmes, procédés et compositions relatifs aux combiomiques
EP3114315A4 (fr) Systèmes de géoguidage et procédés associés
EP3292220A4 (fr) Architecture pipeline de multiprocesseur
EP3197432A4 (fr) Compositions de corticostéroïdes topiques
EP3316685A4 (fr) Compositions pharmaceutiques lyophilisées
EP3307265A4 (fr) Association pharmaceutique et utilisations de cette association
IL259565A (en) Systems and methods for sharing content
EP3240355A4 (fr) Système de détermination de localisation et programme de détermination de localisation
EP3172651A4 (fr) Systèmes et procédés de gestion et de présentation de contenu
MA41022A (fr) Ciblage lysosomial et utilisations correspondantes
EP3149035A4 (fr) Compositions thérapeutiques comprenant de petites molécules thérapeutiques et leurs utilisations
BR112016026143A2 (pt) os métodos e composições compreendendo ácido 10-hidroxi-2-decenóico.
EP3253208A4 (fr) Polythérapies
FI20155827A7 (fi) Paneeli ja paneelijärjestelmä
EP3149052A4 (fr) Dendrimères polyanioniques et non ioniques à base de cyclodextrine